Literature DB >> 16567876

Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes.

V Leimane1, J Leimans.   

Abstract

From 1991 until the end of 1998, the number of patients with tuberculosis in Latvia increased 2.5 times with a simultaneous increase of drug resistant and multidrug resistant tuberculosis (MDR-TB). Descriptive analysis of different TB programme services, activities and strategies including Directly Observed Therapy Short-course (DOTS) for tuberculosis and treatment of MDR-TB, were performed. Data from the state tuberculosis registry, drug resistance surveillance, and the national MDR-TB database were used. The state-funded national tuberculosis control programme (NTAP, Nacionala Tuberkulozes Apkarodanas Programma), based on WHO recommended DOTS strategy, was introduced in Latvia in 1996. The NTAP includes TB control in prisons. Treatment of MDR-TB using second line drugs was started in 1997. Cure rates for TB patients increased from 59.5% in 1996 to 77.5% in 2003. Between 1996 and 2003, more than 200 patients began MDR-TB treatment each year, and the cure rate was between 66% and 73%. Numbers of MDR-TB patients were reduced by more than half during this period. Treatment results including MDR-TB reached the WHO target, with cure rates 85% of newly diagnosed patients. These results demonstrate that MDR-TB treatment and management using the individualised treatment approach can be effectively provided within the overall TB programme on a national scale, to successfully treat a large number of MDR-TB patients. Rapid diagnostic methods combined with early intensified case finding, isolation and infection control measures could decrease transmission of TB and MDR-TB in hospitals and in the community. Highly important that MDR-TB management follows WHO recommendations in order to stop creating drug resistance to first and to second line drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567876

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  4 in total

1.  Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries.

Authors:  David Stuckler; Sanjay Basu; Martin McKee; Lawrence King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-26       Impact factor: 11.205

2.  Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.

Authors:  Helen E Jenkins; Matteo Zignol; Ted Cohen
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

3.  Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis.

Authors:  Daniel E Winetsky; Diana M Negoescu; Emilia H DeMarchis; Olga Almukhamedova; Aizhan Dooronbekova; Dilshod Pulatov; Natalia Vezhnina; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  PLoS Med       Date:  2012-11-27       Impact factor: 11.069

4.  The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia.

Authors:  Thaddeus L Miller; Andra Cirule; Fernando A Wilson; Timothy H Holtz; Vija Riekstina; Kevin P Cain; Patrick K Moonan; Vaira Leimane
Journal:  Cost Eff Resour Alloc       Date:  2013-04-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.